About Mersana Therapeutics (NASDAQ:MRSN)
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio3.69%
Quick Ratio3.69%
Price-To-Earnings
Trailing P/E Ratio-4.93
Forward P/E Ratio-6.27
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.55 million
Price / Sales20.65
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book5.15
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees78
Outstanding Shares22,850,000
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Wednesday, March, 28th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.13. The business had revenue of $3.26 million for the quarter, compared to the consensus estimate of $4.22 million. View Mersana Therapeutics' Earnings History.
What price target have analysts set for MRSN?
5 equities research analysts have issued 1-year price targets for Mersana Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they expect Mersana Therapeutics' share price to reach $26.00 in the next twelve months. View Analyst Ratings for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH) and PTC Therapeutics (PTCT).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Mr. David M. Mott, Exec. Chairman (Age 53)
- Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
- Dr. Timothy B. Lowinger Ph.D., Sr. VP & Chief Scientific Officer (Age 54)
- Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
- Mr. Mikhail Papisov Ph.D., Co-Founder
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Mersana Therapeutics been receiving favorable news coverage?
Headlines about MRSN stock have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mersana Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave news stories about the company an impact score of 44.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $15.86.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $380.84 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mersana Therapeutics (NASDAQ:MRSN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Mersana Therapeutics in the last 12 months. Their average twelve-month price target is $26.00, suggesting that the stock has a possible upside of 63.93%. The high price target for MRSN is $33.00 and the low price target for MRSN is $23.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $26.00 | $26.00 | $23.6667 | $23.6667 |
| Price Target Upside: | 63.93% upside | 48.57% upside | 68.45% upside | 68.45% upside |
Mersana Therapeutics (NASDAQ:MRSN) Consensus Price Target History
Mersana Therapeutics (NASDAQ:MRSN) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Mersana Therapeutics (NASDAQ:MRSN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Mersana Therapeutics (NASDAQ MRSN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 75.59%
Mersana Therapeutics (NASDAQ MRSN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/3/2017 | M James Barrett | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | |  |
(Data available from 1/1/2013 forward)
Mersana Therapeutics (NASDAQ MRSN) News Headlines
| Source: |
|
Mersana Therapeutics (NASDAQ:MRSN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mersana Therapeutics (NASDAQ:MRSN) Income Statement, Balance Sheet and Cash Flow Statement
Mersana Therapeutics (NASDAQ MRSN) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
